SS-31 – Research Peptide

SS-31 (also known as Elamipretide or MTP-131) is a synthetic mitochondria-targeting tetrapeptide developed to selectively localize within the inner mitochondrial membrane. Unlike many investigational peptides that act through cell surface receptors, SS-31 is designed to interact directly with mitochondrial phospholipids—particularly cardiolipin—to study mitochondrial structure, bioenergetics, and cellular resilience under conditions of metabolic stress.

Mitochondria are responsible for the majority of cellular ATP production and play central roles in oxidative metabolism, reactive oxygen species (ROS) regulation, calcium homeostasis, and apoptosis. Because mitochondrial dysfunction has been implicated in numerous age-related and metabolic disorders, SS-31 has become an important research tool for investigating mitochondrial physiology across a wide range of experimental models.

Over the past two decades, SS-31 has progressed from laboratory studies into multiple human clinical trials, making it one of the most extensively investigated mitochondria-targeting peptides currently available for scientific research.

Research Overview

Mitochondrial dysfunction contributes to impaired cellular energy production, increased oxidative stress, and reduced tissue resilience. These processes are increasingly recognized as common features of aging and numerous chronic disease models.

SS-31 was developed to selectively accumulate within mitochondria by binding cardiolipin, a phospholipid unique to the inner mitochondrial membrane. Cardiolipin is essential for maintaining mitochondrial membrane architecture and supporting the function of the electron transport chain.

Rather than stimulating a specific hormone or receptor, SS-31 is primarily investigated for its ability to preserve mitochondrial structure and improve bioenergetic efficiency during cellular stress.

Its broad applicability has led to investigations in cardiovascular physiology, skeletal muscle biology, renal function, ophthalmology, and neurodegenerative research.

Mechanism of Action

SS-31 exerts its biological activity through direct interactions with mitochondrial membranes rather than traditional receptor-mediated signaling.

Cardiolipin Binding

The defining characteristic of SS-31 is its selective affinity for cardiolipin, an essential phospholipid located within the inner mitochondrial membrane.

Experimental studies suggest this interaction may help:

• Stabilize mitochondrial membrane architecture
• Preserve cristae structure
• Support electron transport chain organization
• Improve mitochondrial efficiency

Bioenergetics

By supporting mitochondrial integrity, SS-31 has been investigated for its influence on cellular ATP production.

Researchers continue to study its effects on:

• Oxidative phosphorylation
• Electron transport efficiency
• Cellular energy metabolism
• Metabolic resilience

Oxidative Stress

Reactive oxygen species are natural byproducts of mitochondrial respiration but may accumulate during mitochondrial dysfunction.

Experimental investigations suggest SS-31 may reduce excessive mitochondrial oxidative stress by improving electron transport efficiency rather than functioning as a conventional antioxidant.

Cellular Survival

Laboratory studies indicate that preservation of mitochondrial function may influence signaling pathways involved in apoptosis, inflammation, and tissue recovery following experimental injury.

These mechanisms remain active areas of investigation.

Current Scientific Research

SS-31 has been evaluated in laboratory studies, animal models, and numerous Phase I–III clinical investigations across several research fields.

Mitochondrial Biology

One of the primary applications of SS-31 has been the investigation of mitochondrial function under physiological and pathological conditions.

Researchers continue to study:

• Mitochondrial membrane integrity
• ATP production
• Oxidative phosphorylation
• Cellular bioenergetics
• Reactive oxygen species regulation

Cardiovascular Research

Experimental and clinical studies have explored SS-31 in relation to cardiac mitochondrial function, myocardial energetics, ischemia-reperfusion injury, and heart failure models.

These investigations have provided valuable insight into the relationship between mitochondrial health and cardiovascular physiology.

Skeletal Muscle Research

Because skeletal muscle has high energy demands, SS-31 has become an important tool for studying muscle energetics, mitochondrial adaptation, and age-related declines in physical function.

Ophthalmology and Renal Research

Clinical investigations have also evaluated SS-31 in models involving mitochondrial dysfunction affecting ocular and renal tissues, expanding its relevance across multiple medical disciplines.

Potential Research Applications

Current scientific literature is investigating SS-31 in relation to:

• Mitochondrial biology
• Cellular bioenergetics
• Oxidative stress
• Skeletal muscle physiology
• Cardiovascular research
• Neurodegenerative disease models
• Kidney physiology
• Ocular disease models
• Healthy aging

These represent active areas of scientific investigation and should not be interpreted as established therapeutic indications.

Product Snapshot

Research Category: Mitochondria-Targeting Research Peptide

Alternative Names: Elamipretide, MTP-131, Bendavia

Primary Molecular Target:

• Cardiolipin within the inner mitochondrial membrane

Research Administration Route: Experimental laboratory use

Development Status: Extensive preclinical research with multiple Phase I–III clinical investigations

Evidence Strength: ★★★★★

Extensive mechanistic, translational, and clinical evidence supports SS-31 as one of the most thoroughly studied mitochondrial-targeting peptides currently under investigation.

Key Scientific References

Szeto HH, Schiller PW. Novel Therapies Targeting Inner Mitochondrial Membrane—From Discovery to Clinical Development. Pharmacological Reviews.

A landmark review describing the discovery of the Szeto–Schiller peptide family, their affinity for cardiolipin, and the scientific rationale behind mitochondrial-targeted peptide therapy.

Zhao K, Luo G, Giannelli S, Szeto HH. Mitochondria-Targeted Peptide Prevents Mitochondrial Dysfunction and Oxidative Damage. Journal of Biological Chemistry.

A foundational experimental study demonstrating how SS-31 preserves mitochondrial function, improves ATP production, and reduces oxidative stress in cellular models.

Daubert MA, Yow E, Dunn G, et al. Novel Mitochondria-Targeting Peptide in Heart Failure: A Randomized Clinical Trial. Circulation: Heart Failure.

An important clinical investigation evaluating the effects of Elamipretide on cardiac structure, mitochondrial function, and heart failure physiology.

Szeto HH. First-in-Class Cardiolipin-Protective Compound for Mitochondrial Dysfunction. Journal of Internal Medicine.

A comprehensive review summarizing the molecular mechanisms, translational research, and clinical development of SS-31 across multiple disease models.

PubMed – SS-31 (Elamipretide) Research

A continually updated collection of peer-reviewed publications examining SS-31 across mitochondrial biology, cardiovascular physiology, skeletal muscle research, ophthalmology, nephrology, and healthy aging.

Research Use Statement

For Research Use Only.

SS-31 supplied by Performance Pharma is intended exclusively for laboratory and scientific research conducted by qualified professionals. This product is not approved for human or veterinary use and is not intended to diagnose, treat, cure, or prevent any disease. It should be handled, stored, and used in accordance with applicable laws, regulations, and accepted laboratory research practices.